Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease?

Beltran, M.; Colomer, Ramón; Lipton, Allan; Ali, Suhail M.; Leitzel, Kim

doi:10.1200/jco.2002.99.191

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High serum concentrations of HER2 ECD have been associated with HER2 overexpression [34], increased tumor burden [35], poorer survival [36] and resistance to endocrine therapy and chemotherapy [12,37,38], We found that HER2 ECD positivity was significantly associated with most clinicopathological parameters including tumor size, lymph node involvement, tumor stage, histological grade, chromosome ploidy, ER, PR, and HER2/neu membrane protein overexpression. These results imply that serum HER2 ECD levels may reflect the aggressiveness of the disease better than tissue HER2/neu receptor only.…”

Section: Discussionmentioning

confidence: 94%

Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer

et al. 2012

View full text Add to dashboard Cite

BackgroundSerum levels of the extracellular domain of HER2/neu (HER2 ECD) have been demonstrated to be associated with clinical outcomes. A disintegrin and metalloproteinase-10, a sheddase of HER2/neu, can drive cancer progression and its activity is inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1). However, elevated TIMP-1 expression has been associated with a poor prognosis of breast cancer. Therefore, this study was performed to explore the relationships between serum HER2 ECD, TIMP-1 and clinical outcomes.MethodsOne hundred and eighty-five female breast cancer patients, who received curative mastectomy without neo-adjuvant chemotherapy at Chang-Gung Memorial Hospital, were recruited with informed consent for this study. Pre-operative serum levels of HER2 ECD and TIMP-1 were measured using an enzyme-linked immunosorbent assay.ResultsTwenty-three cases (12.4%) were classified HER2 ECD positive. HER2 ECD positivity was significantly associated with age, lymph node involvement, histological grade, estrogen receptor status, progesterone receptor status, tissue HER2/neu overexpression, and disease-free survival (DFS). In an age, stage, ER and HER2/neu status matched subgroup (N = 41), the serum level of TIMP-1 was significantly associated with HER2 ECD positivity and DFS.ConclusionsA high serum TIMP-1 was significantly associated with HER2 ECD positivity and a poorer DFS among Taiwanese primary breast cancer patients with HER2 overexpression.

show abstract

Section: Discussionmentioning

confidence: 94%

Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The manual and automated ELISA testing methods of serum HER2 ECD are standardized methodologies and are not prone to subjective variable interpretation by a reviewer. Shed HER2 ECD has been detected in the serum from 20% to 40% of patients with metastatic disease [10][11] and high serum concentrations of HER2 ECD have been associated with HER2 overexpression [12], increased tumor burden [13], worse survival [14] and resistance to endocrine therapy and chemotherapy [15][16][17]. On the other hand, HER2 ECD seems to be associated with sensitivity to HER2-targeted agents, such as trastuzumab.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

et al. 2008

View full text Add to dashboard Cite

Background:We explored the correlation between serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) and tissue HER2 status, their relationship with clinicopathological parameters and their impact on disease-free survival (DFS) and overall survival in early breast cancer patients. High serum HER2 ECD levels ( ‡15 ng/ml) were reported in 23 patients (9.0%) and HER2-positive status in tumor tissue was observed in 42 patients (16.4%) with a concordance of 87.1%. High HER2 ECD levels were significantly associated with high histological grade (P = 0.003), stage III (P = 0.008), lymph node involvment (P = 0.035) and negativity of both estrogen (P = 0.016) and progesterone (P = 0.007) receptors. At multivariate analysis, high serum HER2 ECD levels were a significant independent prognostic factor of worse DFS (P = 0.009).Conclusions: A statistically significant association was observed between high serum HER2 ECD levels and worse DFS in early breast cancer patients.

show abstract

Bicalutamide Demonstrates Biologic Effectiveness in Prostate Cancer Cell Lines and Tumor Primary Cultures Irrespective of Her2/neu Expression Levels

Gravina

Festuccia

Millimaggi

et al. 2009

Urology

View full text Add to dashboard Cite

Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease?

Cited by 3 publications

References 14 publications

Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer

Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

Bicalutamide Demonstrates Biologic Effectiveness in Prostate Cancer Cell Lines and Tumor Primary Cultures Irrespective of Her2/neu Expression Levels

Contact Info

Product

Resources

About